These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 30668713)
1. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. Frasca K; Morrow M; Coyle RP; Coleman SS; Ellison L; Bushman LR; Kiser JJ; Zheng JH; Mawhinney S; Anderson PL; Castillo-Mancilla J J Antimicrob Chemother; 2019 May; 74(5):1395-1401. PubMed ID: 30668713 [TBL] [Abstract][Full Text] [Related]
2. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. Morrow M; MaWhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR AIDS; 2021 Oct; 35(12):1949-1956. PubMed ID: 34127580 [TBL] [Abstract][Full Text] [Related]
3. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401 [TBL] [Abstract][Full Text] [Related]
4. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. Castillo-Mancilla JR; Coyle RP; Coleman SS; Morrow M; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL AIDS Res Hum Retroviruses; 2020 Mar; 36(3):173-175. PubMed ID: 31204866 [TBL] [Abstract][Full Text] [Related]
5. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768 [TBL] [Abstract][Full Text] [Related]
6. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288 [TBL] [Abstract][Full Text] [Related]
7. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence. Tsuchiya K; Hayashi Y; Ryu S; Tran HT; Takano M; Tanaka K; Mizushima D; Oka S; Gatanaga H; Hamada A J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine-Based Antiretroviral Therapy (QUANTI-TAF). Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR Clin Infect Dis; 2024 Nov; 79(5):1233-1241. PubMed ID: 38636950 [TBL] [Abstract][Full Text] [Related]
9. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005 [TBL] [Abstract][Full Text] [Related]
10. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238 [TBL] [Abstract][Full Text] [Related]
11. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM; J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578 [TBL] [Abstract][Full Text] [Related]
13. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125 [TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. Morrow M; MaWhinney S; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR J Infect Dis; 2019 Jul; 220(4):635-642. PubMed ID: 30942881 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study. Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682 [TBL] [Abstract][Full Text] [Related]
17. Urine point-of-care tenofovir test demonstrates strong predictive clinical and research utility. Mustanski B; Ryan DT; Spinelli MA; Gandhi M; Newcomb ME AIDS; 2023 Dec; 37(15):2381-2387. PubMed ID: 37696260 [TBL] [Abstract][Full Text] [Related]
18. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282 [TBL] [Abstract][Full Text] [Related]
19. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots. Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029 [TBL] [Abstract][Full Text] [Related]
20. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]